Quantitative MR Biomarkers for Sarcoma Treatment
To determine if MRI imaging can be used to accurately determine if a sarcoma is responding to the type of chemotherapy being used.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Quantitative MR Biomarkers for Sarcoma Treatment|
- To determine if MRI imaging can accurately determine if a sarcoma (tumor)is responding to the type of chemotherapy being used. [ Time Frame: Baseline prior to chemo ] [ Designated as safety issue: No ]To image and evaluate the size of the soft tissue tumor prior to chemotherapy treatment.
- MRI Scan [ Time Frame: 3 weeks post start of chemo and end of chemo ] [ Designated as safety issue: No ]To evaluate the size of the soft tissue tumor after start of chemotherapy to determine if the chemo is having any notable effect on tumor prior to surgery.
|Study Start Date:||July 2009|
|Study Completion Date:||April 2012|
|Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
MRI scan of soft tissue tumor
Procedure: MRI Scan of soft tissue tumor
MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
The purpose of this study is to determine if MRI imaging can be used to accurately determine if a sarcoma is responding to the type of chemotherapy being used or if it is ineffective early on in the treatment; instead of finding this out 2-3 months later. If it is determined that MRI can accurately diagnose tumor response, medications can be switched early on potentially improv8ing the patients'chances of recovery.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01017978
|United States, Michigan|
|University of Michigan Health System|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Gary Luker, M.D.||Universityof Michigan Health Systems|